Introduction
The ubiquitin(Ub)/proteasome system is at the heart of cellular proteolysis, and it uses its degradative capacity to spatially and temporally control and integrate numerous physiological processes in the cell. Unlike the endosomal-lysosomal pathway, which operates in an acidic membrane-bound compartment, the proteasome is found in the cytosol, endoplasmic reticulum, and nucleus and is responsible for degrading the majority of endogenous cellular proteins (Ferrell et al., 2000; Pajonk and McBride, 2001c) . It integrates its functions with other cellular processes, including the action of other proteases. Some of its functions can be assumed by the large oligopeptidase, tripeptidylpeptidase II (Wang et al., 2000) , but targeted disruption of proteasome subunits has shown that, at least in yeast, it remains indispensable for cell viability (Fujiwara et al., 1990; Heinemeyer et al., 1991) . The system may also play a role in extracellular protein degradation, at least in some cases (Sawada et al., 2002) . The proteasome is intimately linked to a flexible, well-developed, and highly efficient ubiquitinylation (Ub) system that marks native proteins for ATPase-dependent destruction. Additionally, it removes misfolded and damaged proteins and closely cooperates with chaperone systems, as well as itself performing chaperonin-like protein unfolding and folding activities.
In recent years, the importance of protein degradation for normal cellular physiology has become increasingly recognized. The rate at which the Ub/proteasome system removes specific proteins will have a marked effect on cell behavior. The absolute nature of proteolysis will confer a directional quality to pathways. At the same time, the system has been recognized to display considerable plasticity that allows it to adapt rapidly and dynamically to multiple cellular challenges, including those posed by irradiation.
Since the activities of the proteasome are vital for life, the molecules responsible for enzymatic activity are well conserved. However, replacement variants have coevolved with the development of specific immune systems. These features, plus rapid changes in the number, type, and location of proteasome subunits lend adaptability to cellular responsiveness (Huang et al., 2002; Rock et al., 2002) . Further, upstream regulatory components that bind to the basic proteasome structure have evolved that modulate activity. Certain of these regulatory components, once considered integral proteasomal structures, have recently been suggested to have additional independent functions (Gillette et al., 2001) . Modulation of proteasome activity has been shown to affect cellular processes as diverse as transcriptional activation (Ejkova and Tansey, 2002; Kang et al., 2002; Ottosen et al., 2002) , cell cycle progression (Yamaguchi and Dutta, 2000) , cell survival (Delic et al., 1998; , DNA repair and chromosome stability (Arnold and Grune, 2002) , receptor-mediated responses to external ligands (Strous and van Kerkhof, 2002) , and antigen presentation through the MHC class I-mediated pathway (Rock et al., 2002) . The diversity and plasticity expressed by the proteasome allows the cell flexibility in making these responses.
There is increasing recognition that diversity within the proteasome-associated Ub system also contributes greatly to the nature of the proteolytic and other functions that are displayed. Further, novel functions of the Ub system are being discovered at a rapid rate, including in endocytosis (Carthew and Xu, 2000) , protein trafficking, transcriptional control, chromosome unwinding, gene silencing, and DNA repair (Pickart, 2001) . Often monoubiquitinylation rather than polyubiquitinylation of substrate is involved, the latter being largely, but perhaps not solely, reserved for targeted proteolysis. Families of Ub-like molecules (Ubl) are being discovered that act antagonistically to, or independently of, Ub to control the fate and function of proteins (Yeh et al., 2000) . A plethora of deubiquitinylating enzymes (Fontana et al., 1982) have been identified that must play key roles in moderating and reversing Ub, although their physiological functions are still largely unknown (Chung and Baek, 1999; Wilkinson, 2000) .
Perhaps the most obvious, but least understood, display of plasticity and diversity in the Ub/proteasome system is the number of times components show up as features in gene microarray data (Hu et al., 2002a) . Clearly, the Ub/proteasome system has the potential to take a unique position as a master controller able to integrate simultaneously multiple physiological signals within a cell. It is not surprising that Ub/deubiquitinylation and proteolysis are now seen to rival phosphorylation/dephosphorylation in importance in cellular physiology, and these processes interface and interact to ensure proper cell function.
This review will focus on how the Ub/proteasome system might regulate cellular responses to irradiation and other oxidative stresses. A characteristic of these responses is that the initial reaction is very rapid and involves post-translational mechanisms. Recent evidence (Pajonk and McBride, 2001c) suggests that the Ub/proteasome system may play a critical role in these, and later, responses to radiation. Discussion of the functional response of the Ub/proteasome system to radiation exposure, however, first requires a brief consideration of diversity within the structural elements of the system.
Structural aspects of the Ub/proteasome system
Proteasomes At the heart of the proteasome is a 20S barrel-shaped core structure comprised of a and b rings with a1-7, b1-7, b1-7, a1-7 symmetry (Figure 1 ). The b1, b5, and b2 subunits catalyze threonine-dependent chymotrypsin-, caspase-, and trypsin-like activities, respectively. The enzymatically active sites are sequestered within the central core of the barrel (Coux, 2002) and are therefore relatively inaccessible. The core 20S structure is inactive in vivo and the transformation to a functionally active proteasome requires a pore in the a ring to be opened. One way this is achieved is by binding 19S regulatory complexes to the ends of the 20S core to form a 26S proteasome that is 2 MDa in size. The 19S particle has 17 subunits that can be further resolved into a base that has six ATPase and several other units and a 'lid' that is homologous to the cop-signalosome complex. With very few exceptions, proteins are marked for destruction through the 26S complex by Ub.
An alternative to the 19S particle as a partner for the 20S proteasome core unit is an 11S heteroheptamer activator complex (PA28 a/b) (Harris et al., 2001; Li and Rechsteiner, 2001 ). Binding of this also opens the pore in the a-ring to allow substrate access, but this structure has a predilection for partially degraded proteins and peptides, rather than intact polyubiquitinylated molecules. Degradation is not ATP dependent. Subcellular location of these structures may vary and critically determine function (Brooks et al., 2000) . Hybrid proteasomes that contain one 19S and one 11S structure attached to the 20S core may play special roles (Tanahashi et al., 2000) .
One specialized function of the proteasome is processing of endogenous molecules for the presentation to cytolytic T cells (CTLs) as MHC class I-bound antigens (Rock et al., 2002) . Since CTLs play a critical role in immune recognition of viruses and tumors, this is an important function. Proteasomal degradation can generate peptides that, after trimming by aminopeptidases, are approximately nine amino acids in size and able to bind in the cleft between the two a-helices of the MHC class I molecule. So important is this process that alternative 20S core enzymes linked to activation of the immune system have coevolved. Treatment of cells with IFN-g, tumor necrosis factor alpha (TNF-a), and other proinflammatory 'danger' signals causes coordinated replacement of the three enzymatic subunits in the core (LMP2 for b1, MECL-1 for b2, LMP7 for b5) (Gaczynska et al., 1994) (Figure 1 ). Cleavage favors production of sites that anchor peptides to MHC class I molecules and alters the nature of the epitopes that are presented to CTLs (Rock et al., 2002) . This has led to these structures being called 'immunoproteasomes.' PA28a and b components are also IFN-g inducible and also, perhaps remarkably, play a major role in determining the nature of the epitope that is presented by the immunoproteasome (Sijts et al., 2000 . A link with the chaperonin system is seen in that hsp90 can substitute in part for lack of PA28 and forms a PA28-independent pathway for MHC class I antigen presentation .
Ubiquitin
Ub involves a hierarchical system requiring, initially, activation of the small 76 amino-acid peptide Ub by a Ub-activating enzyme (E1) in an ATP-dependent reaction ( Figure 2 ). Ub is covalently bound through a highenergy thiolester bond to E1 and then passed to an Ub-conjugating enzyme (UBC) (E2), where it forms a similar thiolester linkage. The final component of the system is an Ub-protein ligase (E3) that confers most of the specificity on the cascade and mediates transfer of Ub moieties to lysine residues in the target protein. E3 enzymes recognize cognate substrates through often illdefined sequence elements referred to as 'degrons.' The thiolester components of this cascade make it susceptible to modification by redox-active agents (Obin et al., 1998) .
There are many groups of E3 ligases. E3a and E3b target basic and bulky hydrophobic N-terminal residues and uncharged N-terminal residues, respectively (Nterminal end rule substrates). The HECT class (homology to the E6AP carboxyl-terminus) directly transfers Ub to their substrates, and their conserved carboxylterminal domain identifies members. The anaphase promoting complex (APC), or cyclosome, group targets mitotic substrates that contain 'destruction box' sequences. The class formed by SCF (Skp1, Cullin, F-box) complexes has a hexameric structure linked to a variable F box protein that mediates substrate recognition, and which targets substrates as diverse as the NF-kB inhibitor, IkBa, the CDK inhibitor, P27
Kip1
, cyclin E, and the transcription factor b-catenin. The class of ringfinger E3 ligases includes c-CBL, which targets CSF-1R, EGFR, and PDGFR, and MDM2, which targets P53 as well as the DNA repair protein BRCA1, and members of the inhibitors of apoptosis (IAP) family. Then there is an ECS (ELONGIN-C-CULLIN-SOCS) group, typified by the von Hippel Lindau protein, pVHL, that also includes the suppressors of cytokine signaling (SOCS), which regulate cytokine receptor kinase signaling pathways and are characterized by a C-terminal SOCS box motif (Kile et al., 2002) .
Efficient protein degradation through the 26S proteasome requires that protein target molecules are polyubiquitinylated. On the other hand, monoubiquitinylation has recently been shown to redirect proteins into specific pathways, such as receptor internalization and endosomal sorting (Carthew and Xu, 2000) . Monoubiquitinylation has also been implicated in chromatin and gene regulation and DNA repair (Pickart, 2001; Salghetti et al., 2001; Haglund et al., 2002) .
Deubiquitinylation is perhaps as important a regulatory process as Ub (reviewed in Chung and Baek, 1999; Wilkinson, 2000) . Genomic sequencing has recognized more than 90 deubiquitinylating cysteine protease enzymes (Fontana et al., 1982) . Deubiquitinylating enzymes (DUBs) play roles in Ub recycling, can reverse Ub, and edit inappropriately ubiquitinylated proteins. Other roles are still largely speculative, but DUB1 and DUB2 are induced by cytokines such as IL-3 and IL-5 and play roles in the cell cycle (Jaster et al., 1999) . Recently, a proteasome subunit that deubiquitinates substrates immediately prior to their degradation has been found Yao and Cohen, 2002) . Another regulatory mechanism is attachment of Ublike molecules (Ubl), such as SUMO ('small Ub-related modifier'), NEDD8, and Apg12, in the place of Ub. Different conjugating enzymes are involved, and the fate of the protein is affected (Yeh et al., 2000) . For example, while activation of NF-kB is generally associated with Ub and destruction of its natural inhibitor IkBa, SUMOylation of IkBa stabilizes the protein and prevents NF-kB activation (Desterro et al., 1998) . Similarly, the rapid turnover of P53 protein following genotoxic stress is mediated largely by the E3 ligase MDM2 (Bottger et al., 1997) . Degradation is inhibited by phosphorylation of P53 or the interaction of MDM2 with P19
ARF (Honda and Yasuda, 1999) . In contrast, SUMOylation of P53 appears to be an alternative route to its activation that may function by relocating the protein to transcriptionally active subnuclear sites (Rodriguez et al., 1999) . It is possible that the mutual antagonism between SUMO-1 and Ub could also result in a molecule existing in stable and unstable pools within different cellular compartments.
The main, but probably not the only, proteasomal subunit to recognize polyubiquitinylated proteins is Rpn10. Following binding, the 19S base unit performs the critical step of ATP-dependent unfolding of the substrate and 'feeding' it into the degradation chamber (Ferrell et al., 2000) . The role of chaperonins, such as heat-shock proteins, in the recognition and unfolding process has yet to be fully evaluated, but the relation is close and has probably coevolved. What is clear is that many proteins have developed an affinity for the proteasome and bind to various subunits, most often within the 19S regulatory structure, to interfere with the degradative process. Since yeast two-hybrid screening is often used to detect such potential interactions, some may be artefactual, but many are real and have considerable potential for modulating proteasome function (Ferrell et al., 2000) .
This brief overview serves to indicate that there is considerable structural diversity within the Ub/proteasome system. Major forces have obviously been at work to conserve enzyme function, while coevolution has occurred with the immune system, the chaperone system, and the E2/E3-based regulatory systems, which have added diversity and flexibility in making responses to external challenge. The evolutionary battle that has been waged can be evidenced by the many strategies that viruses and cancers have developed to avoid immune surveillance or to subvert cellular metabolism that specifically targets the Ub/proteasome system. Discussion of these interactions is not within the province of Figure 2 The ubiquitin system. Ubiquitin is a 76-residue protein that is attached through a C-terminal glycine to an e-amino group of lysine on the substrate following a series of reactions involving activating (E1), conjugating (E2), and ligating (E3) enzymes. The polyubiquitinylated product is then recognized by the 26S proteasome. The Ub is recycled by isopeptidases Role of Ub/proteasome system in cellular responses WH McBride et al this review but they are dealt with elsewhere (Pajonk and McBride, 2001c) . They are worth noting because they illuminate the complexity of the ongoing regulatory interactions. Another complexity when studying the Ub/proteasome system is the marked functional variation between cell types. For example, cancers and rapidly growing embryonic cells generally have higher levels of proteasome activity than their normal well-differentiated counterparts Kanayama et al., 1991; Shimbara et al., 1992; Ichihara et al., 1993) . Proteasome function decreases with age (Ponnappan et al., 1999; Carrard et al., 2002) and is severely affected by microenvironmental factors and disease processes. The close relation between the cytokines IFN-g (Rock et al., 2002) and TNF-a (Pallares-Trujillo et al., 2000) and the proteasome structure and function that has already been mentioned extend to other cytokines and growth factors and their receptors. IL-3 increases proteasome activity (McBride et al., in press ). Proteasome inhibition increases production of IL-6 (Pritts et al., 2002) and IL-8 (Hipp et al., 2002; Wu et al., 2002b) through NF-kB-independent pathways (Wu et al., 2002b) . TGF-b signaling pathways are closely regulated through the Ub/proteasome (Zhang et al., 2002) . Muscle wasting in response to burn injury, cachexia, or sepsis with associated myofibril proteolysis has been associated with increased proteasome activity, an effect that is mediated at least in part by TNF-a, IL-6, and possibly other cytokines (Costelli et al., 2002) .
This plasticity and diversity has to be taken into account when considering how the system behaves when encountering challenges such as those provided by irradiation and oxidative stress.
The Ub/proteasome system and radiation responses
The classical effects of ionizing radiation involve activation of DNA repair, cell cycle arrest, and cell death pathways. Perhaps not surprisingly, there is increasing recognition of interconnections between molecular pathways leading to these apparently distinct functional end points and evidence that they are coordinately regulated in order that cells can make the response most appropriate to the circumstances (Figure 3 ). Since the Ub/proteasome system is intimately involved in signal transduction, DNA repair, cell cycle, and cell death, and since many of the effects of radiation involve changes in protein stability, it seems reasonable to ask what roles this system plays in modulating and coordinating cellular responses to radiation damage (Rolfe et al., 1997; Pajonk and McBride, 2001c ). This question is made all the more pertinent by the discovery that the proteasome may be a direct, redox-sensitive target for ionizing radiation and other oxidative stresses resulting usually in a slowed rate of proteolysis .
DNA repair
The Yeast Genome Deletion Project recently examined the global relation between the Ub/proteasome system and repair of damage caused by ionizing radiation (Bennett et al., 2001) . Of the 130 plus genes (out of 3670) that were identified as influencing radiation responses, around a quarter were involved in protein transcription, trafficking, translation, or degradation. The first report of an intimate relation between DNA repair and Ub was made in 1987. The protein encoded by the RAD6 gene from Saccharomyces cervisiae, which is required for postreplicative DNA repair, among other functions, was shown to have UBC (E2) activity (Jentsch et al., 1987) . Since then, Ub has often been implicated in DNA repair through mechanisms that, interestingly, often seem unrelated to protein degradation. For example, RAD6 is required for the E3 ligases RAD18 and RAD5 to ubiquitinate PCNA (Hoege et al., 2002) . Neither monoubiquitinylation or polyubiquitinylation of PCNA appears to result in its degradation. In contrast, SUMOylation by UBC9 of the same K164 PCNA residue that is normally ubiquitinylated inhibits repair (Hoege et al., 2002) , indicating that DNA repair may be regulated by the balance between SUMOylation and Ub.
A negative regulatory influence of SUMOylation on DNA repair has also been suggested in human cells. Yeast two-hybrid analyses showed that the human homolog of UBC9 binds SUMO-1 and the DNA double-strand break repair proteins RAD51 and RAD52 (Shen et al., 1996) to form nuclear foci, which are a hallmark of DNA damage. Overexpression of SUMO-1 downregulates DNA double-strand breakinduced homologous recombination and lowers cellular resistance to ionizing radiation . UBC9 is present predominantly in the nucleus and at the nuclear pore complex and its relocation to the cytoplasm prevented the formation of RAD51 foci, suggesting that SUMOylation may play a role in RAD51 trafficking (Saitoh et al., 2002) .
BRCA1, a tumor-specific suppressor gene that is mutated in familial forms of breast and ovarian cancer, also tangibly links the Ub/proteasome system to DNA repair by homologous recombination. It forms a heteromeric complex with BARD1. Both molecules have ring-finger domains and express E3 ligase activity. Loss of BRCA1 is associated with sensitivity to ionizing radiation and DNA crosslinking agents, as well as with spontaneous chromosome breakage (Deng and Scott, 2000) . Cancer-predisposing mutations within the BRCA1 RING domain abolish its E3 ligase activity. Unlike wild-type genes, such mutants are unable to reverse radiation hypersensitivity of BRCA1-null human breast cancer cells or to restore radiation-induced G2/M arrest (Ruffner et al., 2001) . The radioprotective effects of BRCA1 are therefore mediated by its E3 ligase activity. The targets for BRCA1 are not fully known, but it interacts with RAD51 and has a role in homologous recombination (Scully, 2001) . It also colocalizes with Fanconi's anemia gene product FANCD2 at sites of DNA damage and monoubiquitinates it (Taniguchi et al., 2002) . The suggestion is that FANCD2/BRCA1/RAD51 complexes participate in Sphase-specific cellular processes, including DNA repair by homologous recombination.
A role for histone Ubiquitinylation in DNA repair has been suggested in numerous reports. For example, BRCA1 colocalizes in nuclear damage foci with the histone variant H2AX, which can serve as its Ub substrate, at least in vitro (Mallery et al., 2002) . Since H2AX mice are sensitive to DNA damage and express chromosome instability (Celeste et al., 2002) , the suggestion is that histone Ubiquitinylation by BRCA1 has a role in chromatin unwinding perhaps by increasing access of repair enzymes. Disruption of histone Ubiquitinylation is known to lead to defects in DNA repair (Robzyk et al., 2000) . The roles that have been proposed for histone Ub are, however, multiple and complex, extending from chromatin uncoiling and gene transcription to gene silencing (Sun and Allis, 2002) , and remain controversial (Jason et al., 2002) .
DNA base excision repair in response to DNA damage also comes under close scrutiny from the Ub/ proteasome system. The proteasome-associated rpn4 that controls expression of genes encoding many proteasome components also modulates expression of a group of DNA base excision repair genes, hinting at a degree of coordinate regulation (Jelinsky et al., 2000) . In addition, poly-(ADP-ribose) polymerase-1 (PARP-1) has been implicated in base excision repair. Its activation is an early event following cell irradiation, and automodified PARP-1 has been found to enhance the ability of proteasomes to remove and degrade oxidatively damaged histones (Arnold and Grune, 2002) . This suggests a link between nucleoprotein turnover and DNA damage and repair that could be important for restoring chromatin structure damaged by irradiation. Physical association of proteasomes with sites of DNA damage has been reported, as has a novel 200 kDa nuclear protein that activates 20S proteasome degradative activity and is expressed in a radiation-induced punctate fashion that is similar to the distribution of DNA repair proteins (Ustrell et al., 2002) .
The nucleotide excision repair (NER) pathway is less involved in the repair of damage caused by ionizing radiation, but is important for the removal of various forms of bulky base damage from DNA, such as that occurs following UV exposure. It contains several proteins that interact with the 26S proteasome, including the RAD4/RAD23 DNA binding complex. The amino-terminal region of the RAD23 protein contains a Ub-like domain (Ubl) that is required for physical interaction between the RAD23 protein and the 26S proteasome in yeast (Schauber et al., 1998) . The Ubl site is required for optimal levels of NER in vivo and links NER to the Ub/proteasome system. RAD4 is ubiquitinylated by RAD23 and its degradation negatively regulates repair (Lommel et al., 2002) . The 19S regulatory complex of the proteasome has also been reported to affect NER, independent of RAD23, of proteolysis, and of binding to the 20S component (Gillette et al., 2001) , indicating that this complex may have unexpected roles in addition to regulating proteolysis.
Cell cycle
Cells normally progress in a timely fashion through the G1 cell cycle phase, DNA replication, sister chromatid separation, and exit from mitosis. Transitions through these phases are controlled by checkpoints that monitor intracellular preparedness for each move. Radiation can cause cell cycle checkpoint arrest in G1/S, S, and G2/ M phases. Cells in G2/M phase are particularly vulnerable to radiation exposure, while cells in S phase are markedly more resistant. Cells arrested at the G1/S checkpoint display greater sensitivity than in the rest of G1 (Dewey et al., 1971 (Dewey et al., , 1972 . These differences in radiosensitivity are large. It requires perhaps three times the dose to achieve the same level of cell kill in the mostsensitive compared with the most resistant cell cycle phase. Cell cycle synchronization of tumor cells could therefore significantly increase the clinical efficacy of radiotherapy. Drugs that have been used to achieve this in preclinical animal models, such as hydroxyurea (Gillette et al., 1970) , have unfortunate adverse toxicity when used clinically, but synchronization may be better achieved by targeting specific elements within the Ub/ proteasome system.
Proteolysis is essential for cell cycle progression and is thought to impose order on the complex series of events that are involved. Proteasome inhibitors therefore have similar effects to radiation in causing cell cycle checkpoint arrest in G1/S, S, and G2/M phases (Wojcik et al., 1996; Machiels et al., 1997; Hashemolhosseini et al., 1998; Kumeda et al., 1999) . Interestingly, cell cycle arrest in response to TGF-b has been reported to require proteasome function and inhibition promotes G1 to S transition under such conditions (Zhang et al., 2002) .
Cell cycle progression is regulated by periodic activation of a family of protein kinases known as cyclin-dependent kinases (CDKs). CDK activity is regulated positively through the interaction of CDKs with their cyclin counterparts, resulting in phosphorylation of target proteins, and negatively through binding of CDK inhibitors (CKI) of the Cip/Kip and INK4 families (Yew, 2001) and by inhibitory phosphorylations such as on Thr14 and Tyr 15 of CDK1. Dephosphorylation of CDKs by phosphatases of the CDC25 family, of which there are 3 homologs A, B, and C (Nilsson and Hoffmann, 2000) , results in their activation. CDC25B and C are regarded as mitotic regulators.
The most obvious manifestation of involvement of the Ub/proteasome pathway in the cell cycle is the periodic oscillation in the expression levels of cyclins. The levels of cyclins that are expressed in a cell are rate limiting, and their removal by the Ub/proteasome system upon completion of their mission is critical for cell cycle progression. For example, phosphorylation of cyclin E allows its recognition by hCDC4, a member of the F box family of proteins (Strohmaier et al., 2001; . This bridges to an SCF E3 ligase that mediates its degradation. If the level of cyclin E is insufficient, cell cycle arrest at G1/S occurs, while too much cyclin E results in premature entry into S phase, mutations, and genomic instability (Spruck et al., 1999) . Irradiation of hematopoietic cancer cells was found to increase cyclin E levels in a time-and dose-dependent manner (Mazumder et al., 2000; Mazumder et al., 2002) , and this could influence cell cycle arrest. Importantly, mutations in the F box protein hCDC4 have been implicated in the pathogenesis of various forms of cancer and may be responsible for some cases of elevated cyclin E levels that are frequently associated with human cancers (Koepp et al., 2001; . Similarly, degradation of cyclin B in anaphase is needed to allow cells to exit from mitosis and genetically engineered stable cell cycle proteins will block this progression (Pines and Rieder, 2001; Wheatley et al., 1997) . Cyclin A is degraded before cyclin B in prometaphase, and excessively high levels of cyclin A can delay mitotic alignment and anaphase (den Elzen and Pines, 2001).
A major feature involved in the degradation of mitotic cyclins is a large multiprotein E3 ligase complex known as the anaphase-promoting complex/cyclosome (APC) (Sudakin et al., 2001) , which is active during M and G1 phases. APC has numerous targets including cyclin B, cyclin A, mitotic kinases, inhibitors of anaphase, spindle-associated proteins, and inhibitors of DNA replication (Cohen-Fix and Koshland, 1997) . Their destruction is normally a prerequisite for cell cycle progression to proceed. The mechanism whereby this class of E3 ligases recognizes substrates is not clear, but recently proteins containing WD40 repeats of the CDC20 family and CDH1 that were found to associate with APC at the metaphase to anaphase transition and in G1, respectively (Visintin et al., 1997) , have gained attention for their ability to recruit substrates for destruction (Vodermaier, 2001; Peters, 2002) . The CDH1-APC complex is inactivated from S phase until the midmitotic phase by phosphorylation by cyclin A-CDK2, allowing timely accumulation of other APC targets before mitosis (Lukas et al., 1999) .
Levels of cyclins are frequently dysregulated in cancer and defective proteasomal degradation has been proposed as one mechanism for cyclin D1 upregulation in breast cancer (Naujokat and Hoffmann, 2002) . Overexpression of cyclin D1 has been reported to radiosensitize cancer cells, a finding that was ascribed to effects on the G2/M transition (Coco Martin et al., 1999) . Caspase cleavage of both cyclin D1-CDK4 and cyclin A-CDK2 has been suggested to promote apoptosis in embryos following ionizing radiation exposure (Finkielstein et al., 2002) , indicating that cell cycle arrest may be linked to apoptosis. Links between cyclin D and transcription have also been suggested (Coqueret, 2002) .
In addition to cyclins, many other positive regulators of cell cycle, such as CDC25A, CDC6, and E2F1 (Diehl et al., 1997; Bastians et al., 1999; Koepp et al., 2001; Yew, 2001; Naujokat and Hoffmann, 2002) , are degraded by the Ub/proteasome system. The same is true for many CDKI negative regulators, such as P21
Kip2 (Blagosklonny et al., 1996; Sheaff et al., 2000) , and P19
INK4d (Thullberg et al., 2000) . Clearly, radiation-induced alterations in protein stability will alter the rate of degradation of critical substrates for cell cycle progression, as might cancerrelated alterations in cell cycle-related proteins.
The first indication of how cell cycle arrest is achieved after ionizing radiation was reported almost a decade ago (el-Deiry et al., 1993) with the discovery that radiation stabilized P53 expression allowing it to activate transcriptionally the CDKI P21 Cip1/Waf1 , which interferes with cyclin E-CDK2-mediated events required for the S-phase transition (reviewed in Iliakis, 1997; Shackelford et al., 1999) . ATM (mutated in ataxia telengiectasia) and ATR (AT mutated and Rad3 related) are essential transducers of the radiation-induced P53-mediated response and of most DNA damage checkpoint responses. Their relative contribution varies with the nature of the DNA lesion (Gatei et al., 2001) . ATM is involved more in responses to ionizing radiation. ATR seems more focused on responses to replication blocks and UV damage (Cliby et al., 1998; Cliby et al., 2002) . AT cells display cell cycle checkpoint defects as well as hypersensitivity to ionizing radiation. Under normal circumstances, P53 turns over rapidly in a cell with a half-life of about 30 min as a result of Ub mediated by UBC5 and the E3 ligase MDM2 Bottger et al., 1997) . Following DNA damage, degradation of P53 is inhibited by several proposed mechanisms including phosphorylation by ATM (Shieh et al., 1997) , or acetylation (Ito et al., 2002) , both of which inhibit the ability of MDM2 to negatively regulate expression, or by increasing the interaction of hMDM2 with P14 ARF (Bothner et al., 2001) . The half-life of P53 increases to around 3.5 h and ubiquitinylated forms increase (Maki and Howley, 1997) . The CDKIs P21
Cip1/Waf1 and P27 Kip1 are also subject to rapid proteasomal degradation following phosphorylation. This enhances the activation of CDK2 and promotes cell cycle progression. An interesting inhibitory effect of NSAIDs on cell cycle progression was recently shown to be caused by the inhibition of proteasome subunit production and function resulting in the upregulation of P27
Kip (Huang et al., 2002) . Proteasome inhibitors, not surprisingly, stabilize P53 and P21 expression (Hideshima and resulting in G1/S arrest (Machiels et al., 1997; Yew, 2001) . Radiation-induced impairment of proteasome function may therefore be involved in the rapid radiation-induced increase in P21 levels that precedes maximum P53 expression (Daino et al., 2002) as well as P53 protein stabilization (Maki and Howley, 1997) . A rapid P53-independent pathway to G1 arrest in response to DNA damage was recently suggested to result from cyclin D1 proteolysis (Agami and Bernards, 2000) . TNF-a may cause G1 arrest through a similar mechanism (Hu et al., 2002b) . These rapid checkpoint arrests are tightly linked to proteolysis and may allow the cell time to mount transcriptional P53-mediated responses.
Recognized targets of ATM activated by ionizing radiation, other than P53, include Nbs1, which is involved in DNA repair, and CHK2 (checkpoint kinase 2). An important target for CHK2 is the CDC25 phosphatase. After ionizing radiation exposure, ATMdependent, CHK2-mediated phosphorylation of CDC25A on Ser123 (Falck et al., 2002) results in its rapid removal by the Ub/proteasome system (Mailand et al., 2000) . Since dephosphorylation of CDK2 is required for its activity, removal of CDC25A phosphatase can block G1 and intra-S phase progression. Defective function of any member of the CHK2-CDC25A-CDK2 cascade results in radioresistant DNA synthesis (RDS), which has long been considered as a hallmark of AT cells. However, cells from mice lacking CHK2 did not display the RDS phenotype, and therefore it was suggested that other factors like CHK1 (checkpoint kinase 1) may compensate for a lack of CHK2 (Takai et al., 2002) . Recently, it was found that CHK1 also regulates both normal S-phase progression and the intra-S-phase checkpoint in response to ionizing radiation via its phosphorylation of CDC25A (Zhao et al., 2002; Sorensen et al., 2003) .
RDS can also be caused by defects in Nbs1 or the Nbs-associated repair protein MRE11, which is another target for ATM (Falck et al., 2002) . The pathway that is involved in cell cycle arrest may be determined in part by the nature of the DNA damage and may evolve with time after initiation of damage. Following UV radiation damage, a G1 arrest pathway that is downstream of ATR and independent of P53-P21 has been described, whose salient feature is proteasome-dependent removal of the CDC25A phosphatase that is activated by CHK1 (Mailand et al., 2000) , although ATR may also be activated slowly after ionizing radiation (Zhou et al., 2002) . Again, because the CHK pathways are posttranslational, they would be expected to be rapid.
The master controller for the G2 to M transition is cyclin B-CDK1 (mitosis promoting factor). Potentially active cyclin B-CDK1 accumulates during the S and G2 phases. It is phosphorylated at Thr161, but is maintained inactive by phosphorylation at Thr14 and Tyr15 by wee1 and Myt1 until the end of G2 (Russell and Nurse, 1987; Norbury et al., 1991) . Dephosphorylation by CDC25C activates CDK1 (Blasina et al., 1997) . Ionizing radiation phosphorylates CDC25C through CHK1 and CHK2, which causes it to bind 14-3-3 sigma and to be sequestered in the cytoplasm, which prevents it from performing its function and results in G2 arrest (Russell and Nurse, 1986; Poon et al., 1997; Chaturvedi et al., 1999) . CDC25A or CDC25B may be able to compensate for CDC25C since the checkpoint appears normal in cells from mice lacking CDC25C (Chen et al., 2001) . CHK1 phosphorylation of CDC25A is also important for the radiation-induced G2 checkpoint (Zhao et al., 2002; Mailand et al., 2002) , and CHK1 and CHK2 appear to play complementary roles in the G2 checkpoint. CHK1 is required for the initiation of G2 arrest following DNA damage , while CHK2 is required for its maintenance (Hirao et al., 2000) . The G2 checkpoint is also dependent on the E3 ligase BRCA1 (Xu et al., 2001) , which has been linked to the activation of CHK1 (Yarden et al., 2002) .
Cell death
Cells lethally injured by radiation typically execute one or more divisions before undergoing 'mitotic death'. The number depends upon the size of the radiation dose, but after a clinically relevant dose of 2 Gy, 2-3 attempts may be made. In contrast to 'mitotic death', certain cells in certain locations, including some lymphocytes, spermatogonia, oligodendrocytes, and cells in the salivary gland, thyroid, intestinal crypt, and hair follicles, undergo rapid 'interphase death' within hours of irradiation. Interphase death is now acknowledged to represent rapid apoptosis. Multiple pathways can trigger different forms of cell death and proteolysis plays a major role in all death pathways. This review will be limited to discussing the role of the Ub/proteasome system in apoptosis induced by irradiation or similar stresses. An excellent more general review of the role of the Ub/proteasome system in apoptosis is available elsewhere (Jesenberger and Jentsch, 2002) .
In certain normal cell types, the proteasome plays a proapoptotic role early in the endogenous pathway to apoptosis induced by irradiation. Primary mouse thymocytes are partially rescued from apoptosis when treated with proteasome inhibitors 1 h, but not 3 h, after g-radiation (Grimm et al., 1996) . Involvement is upstream of central apoptotic events, such as disruption of mitochondrial transmembrane potential, release of cytochrome c, and activation of caspases (Dallaporta et al., 2000) . In contrast, proteasome inhibition had no inhibitory effect on apoptosis induced via the CD95 pathway (Dallaporta et al., 2000) . Similar protective effects of proteasome inhibitors were found in differentiated neuronal cells (Sadoul et al., 1996) and rat cerebellar neurons (Bobba et al., 2002; Canu et al., 2000) undergoing apoptosis in response to deprivation of nerve growth factor and potassium, respectively, but not in cells undergoing necrosis (Bobba et al., 2002) .
One possible explanation for why proteasome inhibition delays radiation-induced apoptosis in thymocytes is that XIAP and c-IAP1, which are E3 ligase members of a family of IAP, autoubiquitinylate and are degraded following irradiation (Yang et al., 2000) . IAPs have multiple roles in apoptosis (Jesenberger and Jentsch, 2002) . For example, XIAP blocks activation of caspases 3, 7, and 9 and ubiquitinylates caspase 3 targeting it for proteasomal degradation (Suzuki et al., 2001a, b) . By preventing removal of IAPs, proteasome inhibitors could slow down the apoptotic process. Proteasome inhibition might also block caspase cleavage of the deubiquitinylating enzyme HAUSP, which has been shown to be involved in thymocyte apoptosis in response to various signals (Vugmeyster et al., 2002) .
In contrast to the proapoptotic role proteasomes play in these normal tissue systems, in tumors and transformed cells proteasomes function to prevent apoptosis. Therefore, treatment of tumor cells with proteasome inhibitors almost invariably activates rapid apoptosis within hours. This process is often accentuated by irradiation, and proteasome inhibitors such as MG132 and PS-341 act as radiosensitizers in vitro and in vivo (Teicher et al., 1999; Pervan et al., 2001a, b; Russo et al., 2001) . The difference between normal and cancer cells in response to proteasome inhibitors suggests that there may be a therapeutic differential to be derived from their use that can be exploited to clinical advantage in cancer treatment.
One theory as to why this apparent difference exists between normal and cancerous cells in their response to proteasome inhibitors is that apoptosis is the natural default pathway for rapidly cycling cells that are unable to remove used components of the cell cycling apparatus. Levels and cleavage products of various cyclins have been implicated in apoptosis induction (Finkielstein et al., 2002; Mazumder et al., 2002) . Also, accumulation of CDKI P27 Kip1 and cyclin E in mice deficient in its E3 ligase Skp2 results in increased spontaneous apoptosis (Nakayama et al., 2000) , and the level of Skp2 in gastric carcinomas modulates the phenotype of the cancer, presumably by affecting P27 expression (Masuda et al., 2002) .
On the other hand, it is tempting to link the difference in response of normal and cancerous cells to proteasome inhibition to the fact that cancers and rapidly growing embryonic cells generally have higher levels of proteasome components and activity than their normal counterparts Kanayama et al., 1991; Shimbara et al., 1992; Ichihara et al., 1993; . Interestingly, when human myelogenous leukemic cells are induced to terminally differentiate, proteasome inhibitors no longer induce apoptosis (Drexler, 1997) . The reason for the enhanced proteasome activity in cancer cells is unknown, but it could be due to increased levels of cytokines and growth factors, reactive oxygen species, or heat-shock factors, and consequent increased proliferation rate, metabolic stress, and dependency on cell survival pathways that are associated with the cancer state. Cells might increase their degradative abilities to cope with crises caused by mutational events and chromosomal instability. Proteasome inhibition would therefore be more likely to precipitate cell death. This theory suggests involvement of a critical survival pathway for each cancer, but this will vary from cancer to cancer. Levels of expression of many important regulators of apoptosis have been shown to be tightly linked to the function of the Ub/ proteasome system. Proteasome inhibition will affect the degradation rate of these critical molecules that may have opposing effects or be differentially expressed by different cell types. It is therefore not surprising that the pathway that appears most involved in apoptosis following proteasome inhibition will vary with the cell type, and other influences.
One apoptotic pathway that might be affected by proteasome inhibition is that involving P53. As has already been mentioned, expression of P53 is regulated in large part by the E3 ligase MDM2 that modulates its degradation rate and its nuclear location (Haupt et al., 1997a; Kubbutat et al., 1997) . Binding of MDMx, P19 ARF , or other inhibitors to MDM2 further moderates degradation (Fuchs et al., 1998) . Following stressinduced activation, P53 down regulates various antiapoptotic proteins, such as BCL-2 (Miyashita et al., 1994; Deveraux et al., 2001 ) and induces expression of various proapoptotic proteins, including BAX, APAF-1, FAS, etc., whose degree of involvement in the apoptotic process appears to vary with the tissue type (Deveraux et al., 2001) . Nontranscriptional mechanisms may also mediate P53-induced apoptosis (Haupt et al., 1997b) . Cell death following proteasome inhibition has however been demonstrated in some circumstances that is independent of P53 (Herrmann et al., 1998; .
The relative amounts or equilibrium between members of the BCL-2 family can either promote cell survival (BCL-2, BCL-XL, A1, MCL-1, and BCL-W) or cell death (BAX, BAK, BCL-XS, and BOK), and this is another possible mechanism for regulating proteasome-mediated apoptosis. BCL-2 is specifically degraded by the 26S proteasome, and although there are ambivalent reports about the role of BCL-2 phosphorylation in apoptosis, there is a clear link with proteasome degradation (Dimmeler et al., 1999; Breitschopf et al., 2000) . The pro-apoptotic factor BAX has also been shown to be under proteasome control (Li and Dou, 2000) . There are reports both for (Grimm et al., 1996; Soldatenkov and Dritschilo, 1997) and against (Herrmann et al., 1998 ) the involvement of a BCL-2 pathway in apoptosis induced by proteasome inhibitors. In lymphoma cells, proteasome inhibition by lactacystin differentially elevated a proapoptotic member of this family, BIK, which accumulated in a ubiquitinylated form in the mitochondria (Marshansky et al., 2001) . Involvement of the BCL-2 family in radiation-induced apoptosis of Ewing's sarcoma has also been suggested (Soldatenkov and Dritschilo, 1997) .
Another survival pathway that is frequently upregulated in cancer is directed by NFk-B, a transcription factor that is sequestered in the cytoplasm by IkB inhibitors until activated to translocate into the nucleus Pahl, 1999; Bussell, 2001 ). Activation of NFk-B most often involves phosphorylation, Ubiquitinylation, and subsequent proteasomal degradation of IkB (reviewed in Karin and Lin, 2002) , although alternative pathways exist (Imbert et al., 1996; Raju et al., 1998) . Since NF-kB is induced by ionizing radiation, it may activate a survival pathway that offers a potential target for tumor radiosensitization (Jung and Dritschilo, 2001) , although this appears not always the case (Pajonk et al., 1999) . NF-kB may provide survival signals in cells by transactivating various antiapoptotic genes, most notably IAPs (Lee and Collins, 2001; Ueda et al., 2001) . NF-kB complexes have recently also been linked to downregulation of the c-JUN amino-terminal kinase (JNK) cascade in mouse embryo fibroblasts responding to TNF-a, which involves transcriptional upregulation of the growth arrest gene GADD45 (De Smaele et al., 2001) . Additionally, radiation-induced NF-kB expression upregulates BCL-2 in PC3 cells and this could be downmodulated by a proapoptotic protein PAR-4, which was found to confer radiosensitivity (Chendil et al., 2002) .
Microarray analysis and mechanistic studies on multiple myeloma cells treated with the proteasome inhibitor PS-341 showed decreased levels of several antiapoptotic proteins and activation of a dual apoptotic pathway of mitochondrial cytochrome c release and caspase 9 activation, as well as a JUN kinase (JNK)-and a FAS/ caspase 8-dependent pathway (Mitsiades et al., 2002) . Heat-shock proteins, P53, and MDM2 levels increase and caspases 3 and 8 may be activated . Caspase inhibitors were able to prevent DNA fragmentation, but not apoptosis caused by lactacystin inhibition of proteasome function in MO7e human myeloid progenitor cells (Wu et al., 1999) , suggesting that caspase activation was a secondary effect of apoptosis rather than being directly involved. MG-132, which inhibits calpain as well as proteasome activity, did not cause caspase 3 activation in PC-3 prostate cancer cells, but the cells still died by apoptosis (Pajonk and McBride, unpublished) . Since MG132 treatment radiosensitized cells, we examined DNA-PKcs levels and DNA-PK activity following MG-132 treatment and irradiation of PC3 cells, but were unable to ascribe radiosensitization to alterations in this DNA repair pathway (Pajonk and McBride, unpublished) .
Overall, it seems likely that there is no single survival pathway that is targeted by proteasome inhibitors that results in apoptosis and is responsible for radiosensitization of cancer cells. Rather, there are likely to be a number. This broad specificity of killing of cancer cells could confer advantages to the clinical use of proteasome inhibitors, especially in combination with cytotoxic agents such as radiation.
Radiation-induced modification of proteasome activity
Recently, Pajonk and McBride showed that ionizing radiation had a rapid inhibitory effect on proteasome function in a variety of cell types, as assessed by the degradation of specific fluorogenic substrates McBride et al., 2002) . The inhibitory effect on proteasome activity that is achieved with exposure to ionizing radiation is not as complete as it is with drugs that target proteasomal enzymatic activity, but in many cell lines a 40-50% impairment in chymotrypsin-like activity was found within 15 min of exposure to doses as low as 5 cGy, and over a wide dose range up to 20 Gy. As a result of evidence discussed earlier on the role of the proteasome in DNA repair, cell cycle arrest, and cell death, these findings have obvious potential implications with respect to radiation-induced cellular responses.
Most of the radiation-induced impairment of proteasome function was associated with 26S activity, with minor effects on the 20S core, suggesting that the 19S regulatory subunit was the main target for radiation. Bulteau et al. (2002) have shown similar rapid impairment of 26S proteasome function after exposure of human keratinocytes to UV-A and UV-B radiation. The inhibition following UV radiation became progressively greater with time, unlike that following ionizing radiation, which recovered to a large extent over a 24 h period of culture (Pajonk, unpublished) .
One possible explanation for radiation-induced impairment of proteasome function is an increase in the expression levels of endogenous inhibitors of proteasome activity. Hsp90 (Conconi and Friguet, 1997) and PI31 (Zaiss et al., 2002) have been shown to inhibit proteasome function, as have other undefined factors found in low molecular weight cytosolic extracts (Pajonk, unpublished) . We have failed to detect any change in the level of endogenous inhibitors following irradiation, as measured in proteasome function assays with fluorogenic substrates. Also, while treatment of cells with geldanamycin, the hsp90 antagonist, increased proteasome function, the inhibitory effects of ionizing irradiation were still observed in the presence of the drug , suggesting that hsp-90 was not responsible. On the other hand, Bulteau et al. (2002) provided evidence that extracts of UV-irradiated keratinocytes, including 4-hydroxy-2-nonenal-modified proteins, inhibited degradation by the proteasome, suggesting that the mechanism may vary with the type of radiation, and perhaps also the dose and therefore the extent of protein damage.
An alternative hypothesis for radiation-induced proteasome impairment is that free radical damage to proteasome-associated molecules blocks substrate processing. Evidence for a direct effect was obtained almost immediately after irradiating isolated purified proteasomes. This impaired their functional activity to an extent similar to that achieved by irradiation of whole cells ). The 26S proteasome or molecules tightly associated with the 26S proteasome therefore appear to serve as direct targets for ionizing radiation.
The extent to which irradiation impairs proteasomal proteolysis may depend upon the composition of the proteasomes. We have recently found that proteasomes from T2 cells, which lack Lmp2 and Lmp7 (and TAP1 and TAP2), appear to be more resistant to the inhibitory effects of irradiation than T1 parental cells (Pervan, unpublished) , suggesting that immunoproteasome structures may be more sensitive, although this conclusion requires to be confirmed in a more direct manner. If proteasome composition is important in radiationinduced impairment of proteasome function, this could help explain differentials between different cell types with respect to radiation-induced gene expression patterns, cell cycle arrest, and apoptosis. It might also have implications for radiation-induced immune suppression, since immune cells, which are involved in MHC class I-mediated antigen processing and presentation, will be affected more than nonimmune cells, which would contain less immunoproteasomes. The concept that molecular substitutions in proteasome structure could redirect and fine-tune cellular responses is indirectly supported by the finding that hsp90 affects constitutive and not immunoproteasomes (Lu et al., 2001) . Mechanisms that protect specific proteasome structures against oxidative damage may exist.
The impairment of proteasome function following exposure to ionizing radiation appears to involve free radical generation. In fact, the proteasome may be a prime sensor of redox changes in the cell. We have recently shown that N-acetyl-l-cysteine (Pajonk et al., 2002b) , tempol, and glutathione (Pervan, unpublished) treatment inhibit proteasome function. Furthermore, concentrations of tempol that were minimally inhibitory could prevent radiation-induced inhibition (Pervan, unpublished) , indicating that the effect of ionizing radiation on 26S proteasome function is mediated by free radicals. The Ub system may also sense redox changes, since intracellular reduced glutathione is required for E1 and E2 enzymes to form the Ubiquitinylation thiol-esters required for Ubiquitinylation (Jahngen-Hodge et al., 1997; Obin et al., 1998) .
Response of the proteasome to other oxidative stresses
Since ionizing radiation appears to affect proteasome function through the generation of free radicals, it is worth briefly examining how the Ub/proteasome system responds to oxidative stress. Cells use reactive oxygen and nitroxide species for multiple important physiological processes, but this has required evolution of means to moderate their toxicity. Antioxidant defense mechanisms include production of enzymes that neutralize free radicals and specific pathways to remove rapidly damaged molecules. The latter involves proteolysis, mainly through non-ATP-dependent proteasomes. Recognition of damaged proteins by proteasomes may be through exposed hydrophobic moieties. Oxidatively modified proteins that are toxic to cells increase with age and in certain pathologic conditions and this has been ascribed to decreased proteasome function (Grune, 2000; Carrard et al., 2002) .
An expected effect of 26S proteasome inhibition is an increase in the level of polyubiquitinylated molecules, whereas inhibition of non-ATPase-dependent proteasomes might lead to accumulation of damaged proteins. One manifestation of protein accumulation is formation of aggresomes, the main components of which are misfolded proteins, Ub, proteasomes, and heat-shock proteins (especially hsp70, hsp90). Cells appear to attempt to protect themselves from toxic intracellular protein overload by activating stress kinases (Meriin et al., 1998; Marcu et al., 2002) and increasing expression of cytosolic heat-shock proteins, which is associated with the acquisition of thermal tolerance (Bush et al., 1997) . A number of disease states have as their hallmark accumulation of ubiquitinylated proteins, especially neurodegenerative diseases, such as Parkinson's (Ii et al., 1997), Alzheimer's (Keller et al., 2000) , Huntington's , and Angelman's syndrome Ishii et al., 1997) .
The response of the Ub/proteasome system following exposure of cells to various oxidative stressors, including hydrogen peroxide, has been examined in some detail (Grune et al., 1995; Grune, 2000) . ATP-dependent degradation of fluorogenic substrates through the 26S proteasome is much more sensitive to hydrogen peroxide treatment than the ATP-and Ub-independent 20S degradation pathway (Reinheckel et al., 1998; Reinheckel et al., 2000; Shringarpure and Davies, 2002; Shringarpure et al., 2002) . Indeed, modest levels of oxidative stress increase the degradation rate of modified proteins (Grune et al., 1995) , as oxidized proteins are preferentially removed by the more resistant 20S proteasome pathway (Shringarpure et al., 2002) . Current evidence therefore suggests a division of labor between the 20S and 26S proteasome in response to oxidative stress that allows the 26S proteasome to slow down degradation of ubiquitinylated proteins and activate pathways leading to appropriate cellular responses without compromising the need to remove potentially cytotoxic nonfunctional proteins, which is performed independently.
In addition to the proteasome minimizing oxidative damage through proteolysis, proteasome inhibition is associated with an increase in reactive oxygen and nitrogen species that may mediate subsequent biological effects Wu et al., 2002a) . Both proteasome inhibition and oxidative stress induce production of heat-shock proteins (Ding and Keller, 2001) . Hyperthermia treatment of cultured myotubes increases degradation of short-and long-lived proteins through the proteasome, with a maximal effect at 41 o C . On the other hand, in other studies heat shock impaired proteasome activity (Bush et al., 1997; Mathew et al., 1998) . Kuckelkorn et al. (2000) have shown that a 1 h exposure of cells to 441C 'locks' 20S proteasomes in their inactive state and does not allow de novo proteasome maturation or further activation of the 26S proteasome by ATP. They also showed rapid intracellular redistribution of proteasomes after heat shock. Our data show that heat exposure preferentially inhibits 26S proteasome function in prostate cancer lines and that heat-induced impairment of proteasome function could be prevented by induction of immunoproteasomes using interferon-g (Pajonk et al, in press ). Variation in the responses of different cells to heat shock are well known and some of this variation may be due to varying levels of different types of heat-shock proteins and proteasome structures. The inhibition of proteasome function experienced by cells following heat exposure could also be responsible for the ability of hyperthermia to inhibit DNA repair processes when administered shortly before ionizing radiation (Locke et al., 2002) .
Cellular consequences of modulation of proteasome activity by radiation
The evidence discussed earlier that ionizing radiation affects proteasome function has obvious potential implications with respect to radiation-induced DNA repair, cell cycle arrest, and cell death, although currently these are somewhat speculative. Decreased rates of proteasome degradation were observed less than 15 min after exposure to radiation in a number of different cancer cell lines . This may be the first adaptive cellular response to damage and it may result in radiation-induced expression of immediate-early genes, such as JUN, FOS, and TNF-a, which occurs within minutes of exposure (Hong et al., 1996 (Hong et al., , 1997 . It should be noted that proteasome inhibition could result in increased expression of these genes at the mRNA, as well as at the protein, level. The reason is that many cytokine, growth factor, and protooncogene mRNAs have AU-rich elements (ARE) in their 3 0 noncoding region. Association of this region with factors such as tristetraprolin or AUF1 promotes their rapid degradation through Ub/proteasome pathways (Laroia et al., 2002) . Radiation-induced impairment of proteasome activity could also be involved in hypersensitivity, adaptive responses, and bystander effects that have been observed following low-dose irradiation, and about which there is currently little mechanistic information (Joiner et al., 1999 (Joiner et al., , 2001 Mothersill and Seymour, 2001 ).
If proteasome degradation pathways are affected by irradiation, one might expect levels of ubiquitinylated proteins to be altered. Indeed, ubiquitinylated cellular P53 levels increase following irradiation (Maki and Howley, 1997) . Expression levels of the cyclin kinase inhibitor P21, which is known to be degraded through the Ub/proteasome system, are also elevated after irradiation, but it is not in a ubiquitinylated form (Maki and Howley, 1997) unlike the case following treatment with proteasome inhibitors. The difference may be that P21 can be unphosphorylated or dephosphorylated as a result of pathways activated by DNA damage, and this would inhibit Ubiquitinylation (Fukuchi et al., 2002) . Irradiation increased Ub mRNA expression and ubiquitinylated nuclear proteins in human lymphocytes (Delic et al., 1993) and in Ewing's sarcoma cells (Soldatenkov and Dritschilo, 1997) , leading to the suggestion that functional changes in the Ub /proteasome system were involved in the radiation-induced apoptosis. Proteins targeted by the N-end rule pathway appeared to be particularly important. On the other hand, deubiquitinylation of nucleosomal histones has been reported following treatment of cancer cells with proteasome inhibitors, and this was ascribed to depletion of unconjugated Ub (Mimnaugh et al., 2000) . Given the complexity of the interactions between proteins linked to the Ub system, the relation of ubiquitinylated proteins to proteasome function will also be complex. A general increase in the expression of all ubiquitinylated proteins is therefore not an expected consequence of radiation-induced proteasome inhibition, but alterations in specific molecular pools would be expected to occur.
One of the most obvious effects of proteasome inhibition on a molecular pathway is the inhibition of NF-kB activation, which is a major mediator of gene transcription for oxidative stress, proinflammatory cytokines, immune, and cell survival responses (reviewed in Karin and Lin, 2002) . This is a complex pathway under multiple levels of regulatory control (Ladner et al., 2003) . The Ub/proteasome system is involved in three ways. First, NF-kB1 (P50) and NF-kB2 (P52) have to be processed from P105 and P100 precursor proteins, respectively, and this is achieved by partial degradation through the Ub/ proteasome. The complete mechanism still has to be elucidated, but a glycine-rich stop region has been reported to interfere with degradation of the aminoterminal region of the P105 molecule allowing the carboxy-terminal to be cleaved. In addition, P105 is targeted for degradation by two unique Ub system recognition motifs, one of which is probably an E3 recognition site. These seem to function under different conditions to provide cells with a low or high amount of P50 Cohen et al., 2001) . Second, Ub is required for the activation of IkB kinase that phosphorylates IkB. Third, the E3 ligase b-TrCP specifically ubiquitinylates phosphorylated IkBa, targeting it for degradation. Inhibition of proteasome function prevents the generation of new NF-kB molecules and stabilizes IkBa expression, preventing NF-kB nuclear localization . Since NF-kB is involved in both inflammatory responses and as a survival factor for cancer cells, proteasome inhibitors are anti-inflammatory agents with potential antitumor activity, in particular for tumors that are addicted to the NF-kB pathway for survival.
Radiation-induced impairment of proteasome function therefore presents a paradox with respect to NF-kB activation. Proteasome inhibition would be expected to prevent NF-kB activation, but numerous studies have shown radiation to activate it (Li and Karin, 1998; Raju et al., 1998) . Activation of NF-kB is considered to mediate radiation-induced proinflammatory responses, and irradiation of cells and tissues increases expression of proinflammatory chemokines (Johnston et al., 2002) and cytokines such as TNF-a (Hallahan et al., 1989; Chiang et al., 1993) , IL-1a and -b (Hong et al., 1994; Hosoi et al., 2001) , IL-5 (Lu-Hesselmann et al., 1997) , IL-6 (Abeyama et al., 1995; Beetz et al., 1997) , GM-CSF (Zhang et al., 1994) , IFN-a (Woloschak et al., 1990) , bFGF (Haimovitz-Friedman et al., 1991) , and VEGF (Gorski et al., 1999; Park et al., 2001) , as well as proinflammatory cell adhesion molecules (ICAM-1 (Behrends et al., 1994; Hong et al., 1994; Gaugler et al., 1997) , E-selectin (Hallahan et al., 1995) , and VCAM-1 (Heckmann et al., 1998) ), prostaglandins and leukotrienes (Eisen et al., 1977; Iwamoto and McBride, 1992) , proteases (Hong et al., 1994; Patel et al., 1998; Fittkau et al., 2001) , and prooxidant species. If the damage is not too severe, this is normally counterbalanced in time by production of anti-inflammatory cytokines, antiproteases, antioxidants, and heat-shock proteins leading to resolution of the inflammation (Barcellos-Hoff, 1993; Sierra-Rivera et al., 1993; Broski and Halloran, 1994; Sadekova et al., 1997; Roedel et al., 2002) .
The apparent paradox extends to the clinic. Although ionizing radiation has recognized proinflammatory effects, it has been used, especially for the first half of the last century, in the treatment of many benign inflammatory as well as hyperproliferative diseases, and in many European countries, it is still a popular treatment modality for such conditions (Trott and Kamprad, 1999) . Such treatments, however, generally use considerably lower doses of radiation than are used in cancer therapy. These considerations prompted investigation into the radiation dose response relation for NF-kB activation and expression of its inhibitor IkBa .
In ECV304 cells, NF-kB was activated only in response to ionizing radiation exposure in the high dose range (X8 Gy) . The same was generally true for radiation-induced ICAM-1 expression, which is considered a downstream readout of NF-kB activity (X4 Gy; Pajonk, unpublished) . IkBa expression did not decrease at any dose, and in fact after 25 cGy IkBa expression was increased, in keeping with what would be expected if irradiation induced proteasome inhibition. ICAM-1 expression was decreased after doses in the range of 25-150 cGy.
Currently, the exact target of ionizing radiation that leads to NF-kB activation is unknown and the mechanism is discussed controversially (Li and Karin, 1998; Raju et al., 1998 ). In the system described above, an IkB super-repressor gene that contains serine-to-alanine mutations at positions 32 and 36 prevented the NF-kB response, indicating that the classical pathway was involved, even though the level of IkBa expression was not decreased after any radiation dose, as it is following, for example, TNF-a treatment.
The interpretation of the dose-response data is that radiation induces proteasome inhibition over a wide dose range, thereby stabilizing IkBa expression, and has an anti-inflammatory effect, but that at high doses a pathway is activated that can overcome this inhibition. Failure to demonstrate a decrease in IkBa when NF-kB is clearly active may be due to slower turnover following irradiation. A recent report showed that inducible nitric oxide synthase (iNOS), which is a key mediator of inflammation downstream of NF-kB, is inhibited by low-dose ionizing radiation and superinduced by high doses -findings that are in keeping with the above concept (Hildebrandt et al., 1998) .
Radiation-induced immunomodulation
The effects of radiation on the immune system have been extensively investigated. Generalized immunosuppressive effects, even after local radiation therapy, are well known, although some studies have shown that radiation, especially at low doses, can be immunostimulatory (North, 1984; Cao et al., 2002) . Immune suppression is most often ascribed to lymphocytes being prone to radiation-induced apoptosis. Immunostimulation at low doses may be due to the relatively high radiosensitivity of suppressor T-cell subsets compared with other lymphocytes (North, 1984) .
If radiation impairs proteasome function, this could affect immune function by pathways other than apoptosis. Maturation of dendritic cells (DCs), the most powerful antigen-presenting cells known, is dependent on proteasome function (Macagno et al., 2001) . Maturation of DCs is an NF-kB-dependent process that is associated with a switch to immunoproteasome expression and is likely to be affected by radiation or oxidative stress (Morelli et al., 2000; Macagno et al., 2001; Lutz and Schuler, 2002) . This could be important because mature DCs may present a different spectrum of epitopes than immature DCs (Morel et al., 2000; Schultz et al., 2002; Sun et al., 2002) . Irradiation may therefore differentially affect mature and immature DCs and constitutive and immunoproteasomes, which could result in a switch in the nature of the epitopes being presented to the immune system. Also, proteasomal processing is required for the production of peptides presented by MHC class I molecules to generate CTL. Recently, evidence has been presented for a surprising increase in the ability of irradiated DCs pulsed in vitro with MART-1 immunodominant peptides to activate tumor-specific T cells (Liao et al., 2002) . This was ascribed to a radiation-induced loss of endogenous processed self-antigen and vacation of MHC class I molecules on the DCs for more efficient exogenous loading. The extent of MHC occupancy by peptides is thought important for T-cell stimulation, in particular for poor binders.
One would expect irradiation to block the endogenous pathway leading to processing and presentation of endogenous antigen by DCs, as is seen using proteasome inhibitors (Rock et al., 2002) . Radiation would also be expected to affect expression of the target antigens on tumor cells that are recognized by the immune system, and specifically by CTL, although this concept is still speculative.
Clinical exploitation of proteasome inhibition in radiation therapy
The Ub system, specifically E2 UBC and E3 ligases, represents a range of specific molecular targets for intervention that are too extensive to consider here (Garber, 2002; Shah et al., 2002; Fang et al., 2003) . However, proteasome inhibitors affect multiple targets and represent a broader based approach to cancer therapy. As discussed earlier, they seem to precipitate apoptosis in tumor cells more readily than in normal cells and therefore have the potential to result in a therapeutic benefit.
The peptide boronic acid compound PS-341 (pyrazlcarbonyl-Phe-Leu-boronate) recently entered clinical trials (Adams, 2002) . Antitumor activity has been demonstrated in murine models of cancer (Cheson, 2002) and in human prostate cancer and multiple myeloma (L 'Allemain, 2002; Mitsiades et al., 2003) . In the latter disease, patients with relapsed refractory disease had a high objective response rate with acceptable toxicity. A Phase III trial comparing PS-341 with dexamethasone in patients with relapsed disease is underway, as are several Phase II investigations (Adams, 2002) . The focus is on hematological malignancies, which is in keeping with high constitutive levels of NF-kB that appear to serve as a survival pathway in these cells and as a target for PS-341. It is unlikely, however, that this is the only target, given the considerations expressed earlier. The side effects of PS-341 are related to dose and timing. In rodents and primates, anorexia, vomiting, and diarrhea that has been observed are presumed due to effects on rapidly proliferating cells in the gastrointestinal tract. However, 80% inhibition of in vivo 20S proteasome activity can be achieved using PS-341 before serious complications arise . Avoiding daily delivery can minimize side effects. Optimal scheduling has yet to be firmly established.
Targeting the proteasome is a novel strategy, although it is likely to be limited in effectiveness without addition of a cytotoxic agent. As proteasome inhibition targets tumor cell survival and DNA repair pathways, proteasome inhibitors generally sensitize to the effects of radiation (Teicher et al., 1999; Pervan et al., 2001a, b; Russo et al., 2001 ) and chemotherapy (Mitsiades et al., 2003) . PS-341 is being combined with gemcitabine or irinotecan in Phase I trials in advanced solid tumors (Adams, 2002) .
Although PS-341 is the only specifically designed proteasome inhibitor to reach clinical trials, there are other drugs that directly affect the Ub/proteasome system that have been used clinically for other purposes. Recently, the HIV protease was shown to share cleavage specificities with the 20S core proteasome (Flexner, 1998) , and the HIV protease inhibitors ritonavir (Lebbe et al., 1998) and saquinavir (Pajonk et al., 2002a) inhibit proteasome function and have antitumor effects. At least the latter radiosensitizes cancer cells and may have clinical utility in this setting . Interestingly, dramatically improved survival rates for AIDS patients suffering from primary central nervous system lymphoma (PCNSL) were found using cranial irradiation along with highly active antiretroviral therapy (HAART), which involves HIV protease inhibitors (Hoffmann et al., 2001) . It is tempting to think that this was achieved by proteasome inhibition resulting in radiosensitization.
Inhibitors of multiple drug resistance gene product 1 (mdr1), like cyclosporine A (Meyer et al., 1997) , rapamycin , vinblastine (Piccinini et al., 2001) , verapamil, and other anthracyclin inhibitors have also been found to inhibit 26S and 20S proteasome function, suggesting an overlap between mdr1 and proteasome specificities that might be usefully exploited (Pajonk et al., in press) . It is tempting to think that some of the immunosuppressive effects of cyclosporine A are achieved through its inhibitory effects on proteasome activity. Interestingly, NSAIDs have also been shown to inhibit proteasome function (Huang et al., 2002) . Although this aspect of their action has yet to be investigated in detail, decreases were found in the immunoproteasome subunits within 24 h of treatment. The immunoproteasome has been linked by others to NF-kB activation (Hayashi et al., 1990; Hayashi and Faustman, 2000) , and the relation between NF-kB and the proteasome activity may in the future prove to be more intimate and reciprocal than is currently evident.
